BackLuye Pharma Group Overview
Luye Pharma Group Ltd.

Luye Pharma Group Return on Equity

Valuation check: LYPHF's ROE is 6.95%, below the sector sector average of 11.85%.

Get informed when a big investor buys or sells

+ Follow

ROE

6.95%

Return on Equity

6.95%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Luye Pharma Group (LYPHF) FAQ

As of the most recent data, LYPHF shows a ROE of 6.95%. That is below the sector sector average of 11.85%. Scroll down for historical charts and peer comparison views.

The its sector sector average ROE is about 11.85%. Luye Pharma Group is at 6.95%, which is lower that average. That is roughly 41.4% below the sector mean. Use the comparison chart on this page to see how LYPHF stacks up against individual peers as well.

Check the historical chart to see whether LYPHF's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Luye Pharma Group with peers to see if the move is company-specific or sector-wide.

Besides this return on equity page, Stockcircle has Luye Pharma Group's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 6.95%) with ownership activity and broader fundamentals.